RT Journal Article
SR Electronic
T1 Comprehensive Systematic Review and Meta-Analysis of Solute Carrier Family 19, Member 1 (SLC19A1) G80A Gene Polymorphism and Its Association with Congenital Heart Defects in Fetal Development: Implications for Genetic Susceptibility and Prenatal Risk Assessment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.01.24314736
DO 10.1101/2024.10.01.24314736
A1 Hernandez, Josh Patrick
A1 Batul, Anjhela Isabel
A1 Dela Cruz, Jerald Wynnes
A1 Siroma, Kyle Gabriel
YR 2024
UL http://medrxiv.org/content/early/2024/10/02/2024.10.01.24314736.abstract
AB Congenital heart defects (CHD) are a major cause of neonatal mortality, highlighting the importance of identifying genetic risk factors in fetal development. The SLC19A1 gene, encoding the reduced folate carrier, is critical for folate metabolism, essential for DNA synthesis during embryogenesis. The G80A polymorphism in SLC19A1 may influence folate transport efficiency and contribute to CHD risk. This meta-analysis aimed to investigate the association between SLC19A1 G80A polymorphism and CHD susceptibility. A systematic review of major databases, including PubMed and EMBASE, was conducted to identify relevant case-control studies. Genetic risk models, such as allele (A vs G), heterozygous (GA vs GG), homozygous (AA vs GG), dominant (GA + AA vs GG), and recessive (AA vs GG + GA), were analyzed using RevMan 5.4.1, with odds ratios (ORs) and 95% confidence intervals (CIs) calculated. Initial results across most genetic models did not show a significant association between G80A polymorphism and CHD. However, after excluding outliers, a moderate association was observed between the GA genotype and increased CHD risk (OR: 1.34, CI: 1.07–1.66). These findings suggest a minimal genetic effect, warranting further research in diverse populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data were openly available before the initiation of the study. file:///C:/Users/Josh/Downloads/s12887-018-1266-9.pdf file:///C:/Users/Josh/Downloads/wang2013.pdf file:///C:/Users/Josh/Downloads/gong2012.pdf https://academic.oup.com/aje/article/158/8/747/63936?login=false https://sci-hub.st/https://link.springer.com/article/10.1007/s00246-015-1188-3 https://pubmed.ncbi.nlm.nih.gov/16019224/ http://humangeneticsgenomics.ir/files/site1/user_files_41a8a4/sujayghosh-A-10-350-2-86ca252.pdfI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript